menu
    • menu
    [{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ BioSenic"},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phebra \/ Phebra","highestDevelopmentStatusID":"8","companyTruncated":"Phebra \/ Phebra"},{"orgOrder":0,"company":"Phebra","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phebra \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Phebra \/ Phebra"},{"orgOrder":0,"company":"Phebra","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phebra \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Phebra \/ Phebra"}]

    Find Clinical Drug Pipeline Developments & Deals by Phebra

    Menu

    Phebra

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Phebra

                            Australia arrow
                            BePharma
                            Not Confirmed

                            Phebra

                            Australia arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : BioSenic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medsenic Subsidiary Signs Licensing Agreement with Phebra PTY Ltd

                            Details : Medsenic and Phebra should facilitate the final steps of manufacturing, clinical confirmation of efficacy and subsequent commercialization of oral ArsciCor (arsenic trioxide) in cGvHD.

                            Product Name : ArsciCor

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            July 02, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : BioSenic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Phebra

                            Australia arrow
                            BePharma
                            Not Confirmed

                            Phebra

                            Australia arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : BioSenic

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BioSenic Reaches Agreement with Phebra on Oral Arsenic Trioxide Development for cGvHD

                            Details : The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.

                            Product Name : ArsciCor

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            January 15, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : BioSenic

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Phebra

                            Australia arrow
                            BePharma
                            Not Confirmed

                            Phebra

                            Australia arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : Medsenic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biosenic Provides Update Regarding Current License Agreement With Phebra

                            Details : Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.

                            Product Name : ArsciCor

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            May 29, 2023

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : Medsenic

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Phebra

                            Australia arrow
                            BePharma
                            Not Confirmed

                            Phebra

                            Australia arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Medsenic

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Medsenic Partners With Phebra for the Clinical Development of the Oral Form of Arscimed® for the Treatment of...

                            Details : Exclusive licensing agreement for the development of a patented formulation of oral arsenic trioxide in the treatment of autoimmune diseases. Initially the oral formulation of arsenic trioxide will target the treatment of patients with chronic graft-vers...

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            June 30, 2021

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Medsenic

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth